Drugmakers exploit cancer’s ‘lethalities’ to make next class of targeted therapies, with first results for Werner drug

Lei Lei Wu

News Reporter

CHICAGO — A new type of targeted cancer drug that blocks a “DNA caretaker” protein called Werner helicase has captured the attention of several big pharma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drugmakers exploit cancer’s ‘lethalities’ to make next class of targeted therapies, with first results for Werner drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

Exclusive: After FDA firings, drug reviewers are asked to volunteer for administrative work

Feng Zhang’s protein nanoparticle startup Aera Therapeutics turns to lipid nanoparticles to jumpstart its pipeline

The inside story of how SalioGen, a startup trying to wrangle ‘jumping genes’ to make medicines, fell apart

White House budget request would cut billions at NIH and CDC, add $500M for MAHA

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for Wern­er drug

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Drugmakers exploit cancer’s ‘lethalities’ to make next class of targeted therapies, with first results for Werner drug